May 23, 2017May 23, 2017

Shire’s SHP647 Shows Promise as Potential Ulcerative Colitis Treatment, Study Finds

News

Treatment with SHP647 (also known as PF-00547659) significantly decreased remission rates in a Phase 2 clinical trial of patients with ulcerative colitis, a type of inflammatory bowel disease (IBD). The ... Read more

June 20, 2016June 20, 2016

Shire to License Rights for Pfizer’s IBD Drug PF-00547659

News

The biotechnology company Shire will license global rights from Pfizer for PF-00547659, a drug under development for patients with moderate-to-severe inflammatory bowel disease (IBD). IBD is a group of conditions characterized by inflammation in the ... Read more